HIMSS TV is your Insider’s Guide to everything HIMSS. We are the world’s first online broadcasting network, focused on global innovation and how information and technology are driving change in healthcare.
  Home
Researching Down syndrome pregnancy and maternal decline
Latest Videos

Researching Down syndrome pregnancy and maternal decline

3:33

Eitan Okun, head of the Paul Feder Laboratory for Alzheimer's Disease Research at Bar-Ilan University, discusses the lab's study on the mechanistic link between pregnancy with a Down syndrome fetus and an elevated risk of maternal cognitive decline.

Read More
Read Less

Latest Videos - Similar Videos View more in Latest Videos

3:36

Physicians could be missing billable opportunities for remote monitoring devices

Electrophysiologists, who implant devices such as pacemakers, need technology to automatically determine when the billing period ends, says Sallie Gustafson, RN, director of Medical Affairs at Murj.

Physicians could be missing billable opportunities for remote monitoring devices
Electrophysiologists, who implant devices such as pacemakers, need technology to automatically determine when the billing period ends, says Sallie Gustafson, RN, director of Medical Affairs at Murj.
3:36
0:57

(Sponsored) Patient-monitoring AI tools' demo to debut at HIMSS26

John Chuang, ONYX Healthcare president, says the company's remote monitoring AI products can be customized to enhance providers' existing workflows and support care coordination.

(Sponsored) Patient-monitoring AI tools' demo to debut at HIMSS26
John Chuang, ONYX Healthcare president, says the company's remote monitoring AI products can be customized to enhance providers' existing workflows and support care coordination.
0:57
7:52

AI is driving down clinical denial rates

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.

AI is driving down clinical denial rates
Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.
7:52